» Articles » PMID: 23329521

Pneumonectomy with and Without Induction Chemo-radiotherapy for Non-small Cell Lung Cancer: Short and Long-term Results from a Single Centre

Overview
Date 2013 Jan 19
PMID 23329521
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objectives:   Pneumonectomy for non small cell lung cancer (NSCLC) after induction radio-chemotherapy (IT) has been associated with high peri-operative risk and its safety and efficacy is still debated. The aim of this retrospective study was to compare short and long-term results of pneumonectomy in patients treated with and without IT (radiotherapy plus chemotherapy) for NSCLC.

Materials And Methods: From 1995 to 2008, 85 consecutive patients underwent pneumonectomy: 49 received pre-operative radiotherapy and chemotherapy (IT group), and 36 patients did not (non-IT group). Peri-operative and long-term outcomes were compared.

Results: Major complications rate was 14.3% for IT group and 16.7% for non-IT group (p = n.s.). Mortality rate was 2% in IT group and 5.5% in non-IT group (p = n.s.). Post-operative hospital stay was significantly longer in the IT group (p < 0.0001) as the need for blood transfusion (p = 0.002). Indeed, the mortality rate was similar in the left- and right-sided operations. 5 years survival was 45.3% for IT group and 38.4% for non-IT group (p = n.s.) and 5 year disease free survival rates were 42.3% vs. 37.8% for the two groups, respectively (p = n.s.). Among the clinical, surgical and pathological features no differences on long term outcomes were found with regards to IT.

Discussion: Pneumonectomy is a feasible and safe procedure even after pre-operative IT. Our results showed a prolonged hospitalization and the need for blood transfusion in the IT group.

Citing Articles

Safe pneumonectomy for locally advanced lung cancer after induction therapy.

Go T, Ikeda T, Yokota N, Fujiwara A, Otsuki Y, Kato A Surg Today. 2021; 52(2):316-323.

PMID: 34318346 DOI: 10.1007/s00595-021-02333-2.


Evaluation of different treatment strategies between right-sided and left-sided pneumonectomy for stage I-IIIA non-small cell lung cancer patients.

Jia B, Zheng Q, Li J, Zhao J, Wu M, An T J Thorac Dis. 2021; 13(3):1799-1812.

PMID: 33841969 PMC: 8024865. DOI: 10.21037/jtd-21-264.


Prognostic Factors and Long-Term Survival in Locally Advanced NSCLC with Pathological Complete Response after Surgical Resection Following Neoadjuvant Therapy.

Lococo F, Sassorossi C, Nachira D, Chiappetta M, Petracca Ciavarella L, Vita E Cancers (Basel). 2020; 12(12).

PMID: 33265905 PMC: 7759985. DOI: 10.3390/cancers12123572.


Efficacy of EGFR-TKIs with or without angiogenesis inhibitors in advanced non-small-cell lung cancer: A systematic review and meta-analysis.

Chen Z, Wei J, Ma X, Yu J J Cancer. 2020; 11(3):686-695.

PMID: 31942192 PMC: 6959046. DOI: 10.7150/jca.34957.


Treatment-Related Predictive and Prognostic Factors in Trimodality Approach in Stage IIIA/N2 Non-Small Cell Lung Cancer.

Jeremic B, Casas F, Dubinsky P, Gomez-Caamano A, Cihoric N, Videtic G Front Oncol. 2018; 8:30.

PMID: 29527511 PMC: 5829546. DOI: 10.3389/fonc.2018.00030.